Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years' Treatment

被引:0
|
作者
Genovese, Mark C. [1 ]
van Hoogstraten, Hubert [2 ]
St John, Gregory [3 ]
Dong, Qunming [2 ]
Jose Gomez-Reino, Juan [4 ]
Maldonado-Cocco, Jose A. [5 ]
Carlos Salazar, Juan [6 ]
Huizinga, Tom W. J. [7 ]
Burmester, Gerd R. [8 ]
机构
[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[2] Sanofi Genzyme, Bridgewater, NJ USA
[3] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[4] Complejo Hosp Univ Santiago de Compostela, Santiago, Spain
[5] Buenos Aires Univ, Sch Med, Buenos Aires, DF, Argentina
[6] Riesgo Fractura SA CAYRE, Bogota, Colombia
[7] Leiden Univ, Med Ctr, Leiden, Netherlands
[8] Charite Univ Med Berlin, Berlin, Germany
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
2509
引用
收藏
页数:3
相关论文
共 50 条
  • [31] Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
    Yen, J. -H.
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2006, 60 (10) : 688 - 692
  • [32] Development of a nursing practice scale for rheumatoid arthritis treatment with biological disease-modifying anti-rheumatic drugs
    Song, Fang
    Nakatani, Hisae
    Sugiyama, Eiji
    Hirata, Shintaro
    [J]. MODERN RHEUMATOLOGY, 2024, 34 (03) : 479 - 487
  • [33] WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS
    Curtis, Jeffrey R.
    Lin, Yong
    Thangavelu, Karthinathan
    Stanislav, Marina
    St John, Gregory
    Gomez-Centeno, Antonio
    Selmi, Carlo
    Huizinga, Thomas
    Antonio Maldonado-Cocco, Jose
    Bukhari, Marwan
    Buttgereit, Frank
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 702 - 703
  • [34] Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis
    Rantalaiho, V.
    Puolakka, K.
    Korpela, M.
    Hannonen, P.
    Mottonen, T.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (04) : S27 - S31
  • [35] Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
    Ernest Choy
    Nick Freemantle
    Clare Proudfoot
    Chieh-I Chen
    Laurence Pollissard
    Andreas Kuznik
    Hubert van Hoogstraten
    Erin Mangan
    Paulo Carita
    Thi-Minh-Thao Huynh
    [J]. Advances in Therapy, 2019, 36 : 817 - 827
  • [36] Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
    Choy, Ernest
    Freemantle, Nick
    Proudfoot, Clare
    Chen, Chieh-I
    Pollissard, Laurence
    Kuznik, Andreas
    van Hoogstraten, Hubert
    Mangan, Erin
    Carita, Paulo
    Thi-Minh-Thao Huynh
    [J]. ADVANCES IN THERAPY, 2019, 36 (04) : 817 - 827
  • [37] Sustained efficacy of repeat treatment courses of rituximab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs
    Emery, P.
    Furst, D. E.
    Ferraccioli, G.
    Udell, J.
    van Vollenhoven, R. F.
    Rowe, K.
    Agarwal, S.
    Shaw, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 430 - 430
  • [38] Long-term outcomes in a Hispanic Population with Rheumatoid Arthritis Receiving Early Therapy with Disease-Modifying Anti-Rheumatic Drugs.
    Santiago-Casas, Yesenia
    Gonzalez-Rivera, Tania C.
    Castro-Santana, Lesliane E.
    Rios, Grissel
    Martinez, David
    Rodriguez, Vanessa E.
    Mayor, Angel M.
    Gonzalez-Alcover, Rafael
    Vila, Luis M.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (12): : 4015 - 4015
  • [39] RHEUMATOID ARTHRITIS TREATMENT WITH COMBINATION OF THREE CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) AND ITS EFFECTIVENESS ON DISEASE CONTROL IN A SHORT TERM COMPARED TO BIOLOGIC DMARDS TREATMENT AFTER PROPENSITY SCORE MATCHING PROCEDURE IMPLEMENTED
    Yoshii, I.
    Chijiwa, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 975 - 976
  • [40] Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent
    Eric Senbel
    Frederick Durand
    Baptiste Roux
    Fatima-Zohra Badaoui
    Bruno Fautrel
    [J]. Rheumatology and Therapy, 2021, 8 : 921 - 935